Biomarker analysis planned for the ongoing Phase 3 brensocatib ASPEN trial (ClinicalTrials.gov Identifier: NCT04594369) and Phase 2 trial in CF (NCT05090904) may inform on whether CatG and PR3 activities are also reduced in sputum to a greater extent than in WBCs. Here, CTSG is linked to cystic fibrosis.